Frost & Sullivan Independent Equity Research

BiolineRx: Continued advancement and execution of BiolineRx’s lead oncology project – BL-8040; sufficient funds to support clinical strategy; stock target price remains at NIS 5.15


Company: BioLineRx        

Sector: Pharmaceuticals

Report type: 2017 Annual Report

For all past reports click here

Published on: 20 March, 2018

Close Menu
Font Resize